Barinthus Biotherapeutics Plc ADRBRNS
Price$0.74

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0-100.0% YoYTTM through 30 Jun 2026
Net Income -$66.4MTTM through 30 Jun 2026
Free Cash Flow -$26.4MTTM through 30 Jun 2026

Margins

Current
Gross Margin0.0%

Returns

-89.5%ROE
-67.7%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio7.17x
Net Debt-$71.9Mnet cash position
Cash & Equivalents$59.3M

Quality Metrics

Altman Z-Score-6.82
Piotroski F-Score1 / 9
Earnings-Beat Rate75.0%

Multi-Year Trend

Revenue
'20'21'22'23'24'25
FY2025: $0
Diluted EPS-$1.02TTM
'20'21'22'23'24'25
FY2025: $-1.64

Dividend

No dividend

Capital Allocation

R&D Spend$16.8M
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.